The National Cancer Institute periodically highlights a particular trial or group of trials out of more than 150 available cancer clinical trials conducted at the National Institutes of Health in Bethesda, Maryland.
Featured trials for a variety of different cancer topics include:
Clinical Trial(s)—Dr. Brigitte Widemann - View all Clinical Trials
- Phase I/II Trial of Mithramycin In Children and Adults With Refractory Extracranial Solid Tumors (Phase I) or Ewing Sarcoma and EWS-FLI1 Fusion Transcript
NCI-12-C-0135, NCT01610570
Clinical Trial(s)—Dr. Udai Kammula - View all Clinical Trials
- Phase II Study in Patients With Metastatic Ocular Melanoma Using a Non-myeloablative Lymphocyte Depleting Regimen of Chemotherapy Followed by Infusion of Autologous Tumor-Infiltrating Lymphocytes With or Without High Dose Aldesleukin
NCI-13-C-0093, NCT01814046
Clinical Trial(s)—Dr. Electron Kebebew - View all Clinical Trials
- A Phase I/II Trial of IL-13-PE in Patients with Treatment Refractory Malignancies With a Focus on Metastatic and Locally Advanced Adrenocortical Carcinoma
NCI-13-C-0046, NCT01766635
- Evaluation of Diagnostic and Prognostic Molecular Markers in Adrenal Neoplasm
NCI-11-C-0149, NCT01348698
- A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Origin
NCI-10-C-0041, NCT01182285
Clinical Trial(s)—Dr. Ann W. Gramza - View all Clinical Trials
- A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC)
NCI-11-C-0027, NCT01240590
Clinical Trial(s)—Dr. Antonio Tito Fojo - View all Clinical Trials
- Efficacy of Adjuvant Mitotane Treatment in Prolonging Recurrence-free Survival in Patients With Adrenocortical Carcinoma at Low-intermediate Risk of Recurrence
NCI-13-C-0083, NCT00777244
Clinical Trial(s)—Dr. Ravi A. Madan - View all Clinical Trials
- A Phase II Study of GI-6207 (CEA Vaccine) in Patients With Recurrent Medullary Thyroid Cancer
NCI-13-C-0095
Clinical Trial(s)—Dr. Brigitte Widemann - View all Clinical Trials
- A Phase I Study of XL184 (Cabozantinib, IND# 116059) in Children and Adolescents With
Recurrent or Refractory Solid Tumors, Including CNS Tumors
NCI-13-C-0042, NCT01709435
- Longitudinal Assessment and Natural History Study of Children and Young Adults With Medullary Thyroid Carcinoma
NCI-12-C-0178 , NCT01660984
Clinical Trial(s)—Dr. Robert J. Kreitman - View all Clinical Trials
- Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia
NCI-10-C-0025, NCT01059786
- Randomized Trial of Cladribine (CdA) With Simultaneous or Delayed Rituximab to Eliminate Hairy Cell Leukemia Minimal Residual Disease
NCI-09-C-0005, NCT00923013
- A Phase I, Multicenter, Dose-Escalation Study of CAT-8015 in Patients With Relapsed or Refractory Hairy Cell Leukemia
NCI-07-C-0130, NCT00462189
- Phase II Study of LMB-2 Immunotoxin in Patients With Recurrent or Refractory CD25-Positive Hairy Cell Leukemia
NCI-06-C-0150, NCT00321555
Clinical Trial(s)—Dr. Lauren V. Wood - View all Clinical Trials
- A Phase I Study of an Adenoviral Transduced Autologous Dendritic Cell Vaccine Expressing Human HER2/neu ECTM in Adults With Tumors With 1-3+ HER2/neu Expression
NCI-13-C-0016, NCT01730118
Clinical Trial(s)—Dr. Robert Yarchoan - View all Clinical Trials
- A Phase I/II Study of the Safety, Pharmacokinetics and Efficacy of Pomalidomide (CC-4047) in the Treatment of Kaposi Sarcoma in Individuals With or Without HIV
NCI-12-C-0047, NCT01495598
- Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi's Sarcoma
NCI-09-C-0130, NCT00923936
Clinical Trial(s)—Dr. Thomas Uldrick - View all Clinical Trials
- Pilot Study of Tocilizumab in Patients With Symptomatic Kaposi Sarcoma Herpesvirus (KSHV)-associated Multicentric Castleman Disease
NCI-11-C-0233, NCT01441063
Clinical Trial(s)—Dr. Wyndham H. Wilson - View all Clinical Trials
- Randomized Phase II Study of Dose-Adjusted EPOCH-Rituximab-Bortezomib Induction Followed by Bortezomib Maintenance Versus Observation in Untreated Mantle Cell Lymphoma With Microarray Profiling and Proteomics
NCI-05-C-0170, NCT00114738
Clinical Trial(s)—Dr. Kieron Dunleavy - View all Clinical Trials
- Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC Positive Diffuse Large B-Cell Lymphoma
NCI-10-C-0052, NCT01092182
Clinical Trial(s)—Dr. Thomas Waldmann - View all Clinical Trials
- Phase I/II Trial of Yttrium-90-labeled Daclizumab (anti-CD25) Radioimmunotherapy With High-dose BEAM Chemotherapy and Autologous Hematopoietic Stem Cell Rescue in Recurrent and Refractory Hodgkin's Lymphoma
NCI-12-C-0003, NCT01468311
Clinical Trial(s)—Dr. Steven A. Rosenberg - View all Clinical Trials
- Assessment of the Safety and Feasibility of Administering T cells Expressing an anti-CD19 Chimeric Antigen Receptor to Patients With B-cell Lymphoma or Leukemia
NCI-09-C-0082, NCT00924326
Clinical Trial(s)—Dr. James N. Kochenderfer - View all Clinical Trials
- Administration of Anti-CD19-Chimeric-Antigen-Receptor-Transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-Cell Malignancies After Allogeneic Stem Cell Transplantation
NCI-10-C-0054, NCT01087294
Clinical Trial(s)—Dr. Daniel H. Fowler - View all Clinical Trials
- Allogeneic HSCT Without Preparative Chemotherapy or With Low-Intensity Preparative Chemotherapy Using Sirolimus and Sirolimus Generated Donor Th2 Cells for Therapy of Refractory Leukemia, Lymphoma, Myeloma, or Myelodysplastic Syndrome
NCI-04-C-0055, NCT00074490
Clinical Trial(s)—Dr. Alan S. Wayne - View all Clinical Trials
- A Pilot Trial of WT1 Peptide-Loaded Allogeneic Dendritic Cell Vaccine and Donor Lymphocyte Infusion for WT1-Expressing Hematologic Malignancies
NCI-08-C-0051, NCT00923910
Clinical Trial(s)—Dr. Christina M. Annunziata - View all Clinical Trials
- Phase II Open Label Non-Randomized Single Agent Study of the SMAC (Second Mitochondrial-Derived Activator of Caspases)-Mimetic Birinapant (TL32711; NSC 756502) in Relapsed Platinum Resistant or Refractory Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
NCI-12-C-0191 , NCT01681368
Search for other clinical trial summaries
Back to Top
